Impaired response to first SARS-CoV-2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib.

ABSTRACT:

SUBMITTER: Guglielmelli P 

PROVIDER: S-EPMC8420430 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature